Liver Function Tests (LFT): Understanding Your Blood Test Series

1. Overview: What this panel reveals and why it is important

The liver function test is not a single assay but a panel of complementary tests that collectively assess three distinct dimensions of hepatic health:

· Hepatocellular integrity – markers of liver cell injury (ALT, AST)

· Cholestatic function – markers of bile flow and biliary tree integrity (ALP, GGT, bilirubin fractions)

· Synthetic capacity – markers of hepatic production (albumin, total protein, sometimes PT/INR)

No single test within the panel is diagnostic in isolation. The power of LFT lies in pattern recognition. The combination of elevated enzymes, the ratio between them, the presence or absence of synthetic dysfunction, and the fraction of bilirubin elevation guides the clinician through a differential diagnosis spanning viral hepatitis, alcohol toxicity, drug injury, biliary obstruction, autoimmune disease, metabolic disorders, cirrhosis, and malignancy.

The LFT panel is also an essential tool for monitoring disease progression and therapeutic response. Serial measurements over time are far more informative than any single snapshot.

---

2. What does it measure

A standard LFT panel typically includes the following components. Reference ranges are laboratory‑specific; values below are approximate adult ranges.

Hepatocellular injury markers:

· Alanine aminotransferase (ALT): 5 – 40 U/L. Highly concentrated in hepatocytes; the most liver‑specific enzyme. Elevation indicates hepatocellular injury.

· Aspartate aminotransferase (AST): 8 – 40 U/L. Found in liver, heart, muscle, kidney, red cells. Less specific than ALT; ratio with ALT aids diagnosis.

Cholestatic markers:

· Alkaline phosphatase (ALP): 30 – 120 U/L. Found in liver (canalicular membrane), bone, intestine, placenta. Elevation suggests biliary obstruction or cholestasis.

· Gamma‑glutamyl transferase (GGT): 5 – 40 U/L. Sensitive but non‑specific; elevated in cholestasis, alcohol use, and many liver diseases. Used to confirm hepatic origin of elevated ALP.

· Bilirubin – total, direct (conjugated), indirect (unconjugated): Total 0.3 – 1.2 mg/dL; direct <0.3 mg/dL. Direct fraction distinguishes obstructive/haemolytic patterns.

Synthetic function markers:

· Albumin: 3.5 – 5.0 g/dL. Synthesised exclusively by hepatocytes; half‑life 18–21 days. Low albumin indicates chronic liver disease, malnutrition, or protein loss.

· Total protein: 6.0 – 8.0 g/dL. Albumin plus globulins; A/G ratio derived.

Additional tests sometimes included:

· Prothrombin time / INR: Not always on chemistry LFT panel but essential for liver synthetic function (clotting factors II, VII, IX, X). Prolonged PT indicates severe acute or chronic liver failure.

· Lactate dehydrogenase (LDH): Non‑specific; elevated in ischaemic hepatitis, haemolysis, malignancy.

---

3. Other factors connected to this panel

Preanalytical variables:

· Haemolysis: Falsely elevates AST, LDH, and sometimes bilirubin; can interfere with some ALP assays.

· Lipaemia: Interferes with spectrophotometric assays for bilirubin and total protein.

· Prolonged tourniquet use: Haemoconcentration elevates albumin and total protein.

· Sample storage: Bilirubin is photolabile – protect from light. AST and ALT stable 3–5 days at 4°C.

Medications affecting LFT components:

· Elevate ALT/AST: Statins (1–3%, dose‑dependent), acetaminophen (toxic dose), isoniazid, nitrofurantoin, valproate, certain antibiotics, anticonvulsants, NSAIDs.

· Elevate ALP/GGT: Phenytoin, carbamazepine, rifampin, oral contraceptives (cholestatic), erythromycin, amoxicillin‑clavulanate.

· Elevate bilirubin: Rifampin, atazanavir, probenecid (unconjugated); oestrogens, chlorpromazine (conjugated).

· Lower albumin: Chronic corticosteroid use, oral contraceptives.

· Interfere with assays: High‑dose vitamin C (falsely low bilirubin, creatinine).

Physiological and demographic factors:

· Age: Newborns have physiological hyperbilirubinaemia; children have higher ALP (bone growth); elderly have slightly lower albumin.

· Pregnancy: ALP rises (placental isoform); albumin falls (haemodilution); mild transaminase elevation in hyperemesis gravidarum; GGT normal or slightly decreased.

· Sex: Females have slightly lower ALT and AST; GGT lower in women.

· Race/ethnicity: Gilbert syndrome (unconjugated hyperbilirubinaemia) common in Caucasians; African Americans may have slightly higher baseline AST.

· Body mass index: Obesity associated with higher ALT (NAFLD).

· Exercise: Strenuous exercise elevates AST (muscle) and ALT (less so); ratio >1.5.

---

4. Disorders related to abnormal values: Pattern recognition

The LFT panel is best interpreted by pattern, not by individual abnormalities. The following five patterns account for >90% of abnormal LFTs encountered in clinical practice.

a. Hepatocellular pattern

Laboratory profile:

· ALT and AST elevated disproportionately to ALP

· AST:ALT ratio variable

· ALP normal or mildly elevated (<3× upper limit)

· Bilirubin may be normal or elevated; if elevated, direct and indirect fractions both increased

· Synthetic function (albumin, PT) normal unless severe or chronic

Differential diagnosis:

· Acute viral hepatitis (A, B, C, E, EBV, CMV)

· Drug‑induced liver injury (acetaminophen, isoniazid, NSAIDs)

· Ischaemic hepatitis (shock liver) – AST/ALT often >1000 U/L, rapid rise and fall

· Autoimmune hepatitis

· Wilson disease (young patients, AST > ALT, low ALP)

· Non‑alcoholic fatty liver disease (NAFLD) – mild elevation, ALT > AST, ratio <1.0

Outlier scenarios:

· AST/ALT >1000 U/L: Ischaemic hepatitis, acetaminophen toxicity, acute viral hepatitis, autoimmune hepatitis flare. Alcoholic hepatitis rarely exceeds 300 U/L.

· AST/ALT >2.0 with AST <300 U/L: Strongly suggests alcoholic liver disease.

· ALT > AST with mild elevation: Most likely NAFLD; consider chronic hepatitis C.

b. Cholestatic pattern

Laboratory profile:

· ALP and GGT elevated disproportionately to ALT/AST

· ALT/AST normal or mildly elevated (<2–3× upper limit)

· Bilirubin often elevated, predominantly direct (conjugated)

· GGT confirms hepatic origin of ALP (elevated in liver, normal in bone disease)

Differential diagnosis:

· Extrahepatic obstruction: Choledocholithiasis, biliary stricture, pancreatic cancer, cholangiocarcinoma, Mirizzi syndrome

· Intrahepatic cholestasis: Primary biliary cholangitis (AMA positive), primary sclerosing cholangitis (PSC, associated with IBD), drug‑induced cholestasis (amoxicillin‑clavulanate, chlorpromazine), sepsis cholestasis, total parenteral nutrition, infiltrative diseases (sarcoidosis, amyloidosis, lymphoma)

· Benign genetic disorders: Dubin‑Johnson syndrome, Rotor syndrome (conjugated hyperbilirubinaemia, normal ALP/GGT)

Outlier scenarios:

· Isolated hyperbilirubinaemia (normal ALP/GGT, normal ALT/AST): Gilbert syndrome (unconjugated), Dubin‑Johnson/Rotor (conjugated). No treatment.

· Markedly elevated ALP with normal GGT: Consider bone source (Paget disease, fractures, osteomalacia, metastatic prostate cancer).

· Elevated ALP/GGT with normal bilirubin: Early cholestasis, partial obstruction, drug effect, infiltrative disease, PBC/PSC.

c. Mixed hepatocellular‑cholestatic pattern

Laboratory profile:

· Both hepatocellular enzymes (ALT/AST) and cholestatic enzymes (ALP/GGT) elevated, neither predominating

· Ratio ALT/ALP <5 but >2 (some definitions)

· Bilirubin often elevated

Differential diagnosis:

· Choledocholithiasis with ascending cholangitis

· Drug‑induced liver injury with mixed features

· Viral hepatitis with cholestatic phase (especially hepatitis A, EBV)

· Alcohol‑related hepatitis with cholestasis

· Malignant biliary obstruction with secondary hepatocellular injury

d. Synthetic dysfunction pattern

Laboratory profile:

· Low albumin (chronic)

· Prolonged PT/INR (acute or chronic)

· Normal or only mildly elevated transaminases

· Bilirubin may be elevated or normal

Differential diagnosis:

· Cirrhosis – any aetiology; synthetic failure is a late manifestation

· Acute liver failure – rapid onset of PT prolongation and encephalopathy; transaminases may be very high initially then fall

· Malnutrition / protein‑calorie malnutrition – low albumin, normal PT, normal transaminases

· Nephrotic syndrome / protein‑losing enteropathy – low albumin, normal PT, normal transaminases, urinary or faecal protein loss

Outlier scenarios:

· Isolated hypoalbuminaemia with normal enzymes and normal PT: Suspect extrahepatic protein loss (renal, gut) or malnutrition.

· Prolonged PT with normal albumin: Acute severe liver injury (e.g., acetaminophen, acute viral hepatitis) – albumin half‑life 18 days, PT factor VII half‑life 6 hours; PT rises acutely, albumin remains normal until days later.

e. Isolated hyperbilirubinaemia

Laboratory profile:

· Elevated bilirubin

· Normal ALT/AST, ALP/GGT, albumin, PT

· Direct fraction distinguishes unconjugated vs conjugated

Differential diagnosis:

· Unconjugated: Gilbert syndrome (mild, <3 mg/dL, fluctuates), haemolysis (elevated LDH, reticulocytosis, low haptoglobin), Crigler‑Najjar (rare, severe), drugs (rifampin, probenecid)

· Conjugated: Dubin‑Johnson syndrome, Rotor syndrome (both benign), early cholestasis without enzyme elevation (rare)

---

5. Best way to address aberrant levels: A holistic approach

Critical principle: The LFT panel is a constellation, not a collection of independent stars. Do not treat individual numbers – treat the pattern, and treat the patient. Empiric therapy without a diagnosis is rarely appropriate and may be dangerous.

a. Diagnostic algorithm, not therapeutic trial

Step 1: Confirm the abnormality

· Repeat the panel if initial abnormality is mild, isolated, or suspected to be artefactual (haemolysis, post‑exercise, fasting Gilbert).

· Exclude extrahepatic causes: muscle injury (CK), bone disease (bone‑specific ALP, calcium), haemolysis (LDH, haptoglobin, smear).

Step 2: Identify the dominant pattern

· Hepatocellular, cholestatic, mixed, synthetic, or isolated hyperbilirubinaemia.

Step 3: Narrow the differential

· Hepatocellular: Viral serologies (HAV, HBV, HCV, HEV, EBV, CMV), autoantibodies (ANA, ASMA, LKM1), ceruloplasmin (age <40), iron studies, alpha‑1 antitrypsin, history of alcohol, drugs, metabolic syndrome.

· Cholestatic: Ultrasound (bile duct dilation, stones, mass); if intrahepatic: AMA, MRCP, liver biopsy.

· Synthetic dysfunction: Liver ultrasound (cirrhosis, portal hypertension), transient elastography, endoscopy for varices.

· Isolated hyperbilirubinaemia: Fractionate bilirubin; if unconjugated, exclude haemolysis; if conjugated and normal enzymes, consider Dubin‑Johnson/Rotor (genetic testing, urinary coproporphyrins).

Step 4: Treat the underlying cause

· Viral hepatitis: Antivirals (HBV, HCV), supportive care (HAV, HEV).

· Alcohol: Abstinence, nutritional support, corticosteroids for severe alcoholic hepatitis.

· NAFLD: Weight loss, vitamin E (non‑diabetic NASH), pioglitazone, Mediterranean diet.

· Drug‑induced: Discontinue offending agent; N‑acetylcysteine for acetaminophen.

· Autoimmune hepatitis: Corticosteroids ± azathioprine.

· Biliary obstruction: ERCP, sphincterotomy, stenting, surgical resection.

· PBC: Ursodeoxycholic acid (UDCA).

· PSC: UDCA (improves enzymes, not survival), endoscopic management of strictures.

· Cirrhosis: Treat complication (ascites, varices, encephalopathy); consider transplant.

· Gilbert/Dubin‑Johnson/Rotor: Reassurance; no treatment.

b. Role of supplements and holistic medicine – supportive only

Hepatocellular injury (adjunctive):

· N‑acetylcysteine: Beyond acetaminophen toxicity, may improve transplant‑free survival in non‑acetaminophen acute liver failure. Use under hepatologist guidance.

· Milk thistle (silymarin): Modest ALT reduction in alcoholic and viral hepatitis; no mortality benefit. Do not delay definitive therapy.

· Vitamin E: Only for biopsy‑proven NASH in non‑diabetics (800 IU/day). Not for simple steatosis.

· Curcumin (bioavailable): Anti‑inflammatory; may modestly reduce ALT in NAFLD.

· Vitamin D3: Deficiency universal in chronic liver disease; supplement with lichen‑derived cholecalciferol.

Cholestasis (adjunctive):

· Ursodeoxycholic acid (UDCA): First‑line for PBC; also used in intrahepatic cholestasis of pregnancy, cystic fibrosis liver disease. Not a supplement – prescription medication.

· Vitamin D3, calcium: Prevent metabolic bone disease in chronic cholestasis.

· Fat‑soluble vitamins (A, D, E, K): Supplement if deficient (PBC, chronic cholestasis).

Synthetic dysfunction:

· Branched‑chain amino acids (BCAAs): Improve albumin and reduce encephalopathy in cirrhosis; modest effect.

· Zinc: Deficiency common in cirrhosis; supplementation (50 mg/day) may improve albumin and encephalopathy.

· Nutritional support: High‑protein (1.2–1.5 g/kg/day) unless encephalopathic; plant‑based protein preferred.

Herbs and Phytochemicals from Indian subcontinent (adjunctive, not primary):

· Kutki (Picrorhiza kurroa), Bhumyamalaki (Phyllanthus niruri), Guduchi (Tinospora cordifolia): Traditional hepatoprotective herbs; limited evidence, mostly low‑quality trials. May be used under qualified practitioner guidance only after definitive diagnosis and in conjunction with standard care.

· Never use in acute severe hepatitis, acute liver failure, or without medical supervision.

· Avoid all hepatotoxic herbs: kava, comfrey, chaparral, germander, pennyroyal, high‑dose green tea extract.

c. Dietary and lifestyle approach (plant‑forward, ecologically sustainable)

Core principles for all liver disorders:

· Mediterranean diet – highest evidence level for NAFLD, reduces hepatic steatosis, inflammation, and fibrosis.

· Avoid alcohol completely – no safe threshold in liver disease.

· Avoid ultra‑processed foods, trans fats, high‑fructose corn syrup, red and processed meat.

· Maintain healthy weight – 5–10% weight loss significantly improves steatosis and enzymes.

· Regular physical activity – 150 minutes/week moderate aerobic + resistance training.

Plant‑based protein sources (ecologically responsible):

· Legumes, tofu, tempeh, edamame, mycoprotein, quinoa, hemp seeds, spirulina, chlorella.

· Adequate protein intake is essential in cirrhosis (1.2–1.5 g/kg/day); protein restriction is harmful.

Specific considerations:

· Haemochromatosis: Avoid iron supplements, vitamin C supplements (>500 mg), raw shellfish.

· Wilson disease: Avoid high‑copper foods during initial chelation (liver, shellfish, nuts, chocolate, mushrooms, dried fruit).

· NAFLD: Eliminate sugary beverages; emphasise whole grains, vegetables, unsaturated fats.

· PBC/PSC: Fat‑soluble vitamin supplementation as needed; calcium and vitamin D for bone health.

Note on substances with addiction potential:

This guide does not recommend tea, coffee, or any caffeinated beverages. While some studies have reported associations between coffee consumption and reduced liver enzyme levels or slower fibrosis progression, such substances carry addiction potential and can lead to unintended overstimulation of the nervous system, masking fatigue and promoting unsustainable energy expenditure. Non‑addictive lifestyle measures – particularly a whole‑food, plant‑based diet, regular exercise, and maintenance of healthy body weight – are both safer and more foundational for long‑term liver health. No addictive substance is necessary for the management of liver disease.

---

6. How soon can one expect improvement and the ideal time frame to retest

Improvement timelines are pattern‑ and cause‑dependent.

Hepatocellular pattern:

· Ischaemic hepatitis: AST/ALT fall >50% within 24–72 hours of haemodynamic recovery.

· Acute viral hepatitis: Enzymes normalise over 4–8 weeks.

· Acetaminophen toxicity (NAC): AST peaks at 72–96 hours, then declines over 1–2 weeks.

· Alcoholic hepatitis (abstinence + steroids): AST declines over 2–4 weeks; Lille score at day 7 predicts response.

· Autoimmune hepatitis (steroids): AST/ALT improve within 2–4 weeks; normalisation target 6–12 months.

· NAFLD (lifestyle): ALT reduction at 3–6 months with ≥5% weight loss.

Cholestatic pattern:

· Bile duct obstruction (relieved): ALP falls over days to weeks; bilirubin normalises 1–2 weeks.

· PBC (UDCA): ALP declines over 3–6 months; normalisation in 40% at 2 years.

Synthetic dysfunction:

· Acute liver failure (recovery): PT normalises over days to weeks; albumin rises slowly (weeks to months).

· Cirrhosis (compensated, treated): Albumin may increase modestly over months with nutritional support and disease control; often does not normalise.

Retesting intervals:

· Acute presentations (jaundice, markedly elevated enzymes): Repeat in 1–2 weeks, or sooner (48–72 hours) if ischaemic hepatitis or fulminant suspected.

· Chronic stable disease (NAFLD, compensated cirrhosis): Repeat every 6–12 months.

· Monitoring therapy (autoimmune hepatitis, viral hepatitis): Repeat at 1, 3, 6 months, then every 6–12 months.

· Isolated benign hyperbilirubinaemia (Gilbert, Dubin‑Johnson): Retesting not indicated once diagnosis confirmed.

---

Conclusion

The liver function test panel is a masterpiece of clinical economy – four to eight blood tests that, when woven together, narrate the story of the liver: its injury, its struggle with bile, its synthetic exhaustion, and its genetic quirks. The panel does not diagnose; it patterns. And each pattern – hepatocellular, cholestatic, mixed, synthetic, isolated bilirubin – is a map to a specific diagnostic territory.

To treat an LFT abnormality without first identifying the pattern and its cause is to navigate without a map. Empiric silymarin for elevated ALT may delay hepatitis C treatment; ursodiol for biliary dilation may mask an obstructing pancreatic cancer; corticosteroids for autoimmune‑like hepatitis may worsen Wilson disease.

The holistic management of abnormal LFTs is therefore diagnostic rigour first, cause‑specific therapy second, and supportive, ecologically sustainable lifestyle and nutritional interventions third. The plant‑forward Mediterranean diet, abstinence from alcohol, weight management, regular physical activity, and judicious use of adjunctive supplements (active folate, methylcobalamin, lichen‑derived vitamin D, algae‑sourced omega‑3, and traditional Indian herbs under qualified guidance) provide a foundation for liver health that is both effective and free from addiction potential. No addictive substance – whether caffeine, alcohol, or nicotine – is required or recommended.

As with all blood tests, the LFT panel is a conversation between the laboratory and the clinician. Listen to the pattern. Investigate the outlier. Treat the patient.

---x---x

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

Special note on protein in liver disease:

Plant‑based protein sources are nutritionally adequate for all liver diseases requiring increased protein intake, including cirrhosis and malnutrition. Soy, legumes, mycoprotein, and algae provide complete or complementary amino acid profiles. Meat and fish are neither necessary nor preferred.

Special note on addictive substances:

This guide does not recommend tea, coffee, alcohol, or tobacco in any form. While some observational studies have associated coffee with favourable liver outcomes, the addiction potential and risk of unintended physiological strain outweigh any putative benefit. Safe, non‑addictive lifestyle interventions are always preferred.

-x-x